医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nearly 2 Million Airline Seats Affected by New Travel Ban, According to OAG Analysis

2020年03月13日 AM01:52
このエントリーをはてなブックマークに追加


 

LONDON & SINGAPORE

OAG, the world’s leading provider of travel data and insight, released its latest analysis on the global impact of the coronavirus on the air travel market.

The Europe to United States travel ban will have far-reaching implications for the global aviation industry. The ban will affect 10.9% of all international flights and 16.9% of all scheduled international seats between the United States and Schengen countries. Overall, 6,747 flights and roughly 2 million seats will be affected each way over the next four weeks.

Delta and United Airlines are the most affected U.S. carriers. Together, they account for 31% of the affected flights. Lufthansa is the most affected European airline (13%). The most affected European countries are Germany, France and the Netherlands—which service 57% of all flights between the Schengen Area and U.S.

“COVID-19 has caused the single largest disruption to the air travel market ever,” said John Grant, senior aviation analyst at OAG. “The situation is extremely fluid, with travel restrictions, capacity and airline schedules changing by the day. Expect a significant amount of cancellations from U.S. and European carriers in the coming days.”

Looking ahead to scheduled capacity for April 2020, as of March 12, 2020, there are currently 13,169 scheduled, one-way flights from Europe to the U.S., including the United Kingdom. The countries with the most scheduled flights include the UK (4,121 flights), Germany (1741 flights), France (1,570 flights), Netherlands (1,212 flights) and Spain (851 flights).

For more information, visit OAG’s dedicated page: https://www.oag.com/coronavirus-airline-schedules-data

About OAG

OAG is a leading global travel data provider, that has been powering the growth and innovation of the air travel ecosystem since 1929.

Headquartered in the UK, OAG has global operations in the USA, Singapore, Japan, Lithuania and China.

For more information, visit: www.oag.com and follow us on Twitter @OAG Aviation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200312005629/en/

CONTACT

Media Contact:

UK & ROW

Katy Ludwell

Marketing Manager

pressoffice@oag.com

同じカテゴリーの記事 

  • Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)